Biocon Limited has successfully completed the buyback of commercial papers worth Rs. 2,000.00 crore on January 30, 2026. The company fulfilled its payment obligations for two separate commercial paper issues under SEBI Master Circular compliance, marking the completion of a significant debt management exercise.

Buyback Transaction Details

The commercial paper buyback involved two distinct ISINs with different face values and purposes. The company completed both transactions on the same date, demonstrating efficient debt management capabilities.

Fund Utilization and Purpose

The commercial papers were issued for specific corporate purposes as disclosed in the original offer documents. The larger issue of Rs. 1,800.00 crore was utilized for acquisition of equity shares in subsidiary, while the Rs. 200.00 crore issue funded redemption of debentures and acquisition of debentures issued by subsidiary.

Regulatory Compliance

Biocon confirmed adherence to all regulatory requirements under SEBI Master Circular no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025. The company certified that asset classification of fund-based facilities from banks and financial institutions continued to be "Standard" and no material changes occurred in financial status affecting credit rating.

Corporate Governance

The buyback was executed in accordance with guidelines issued by Fixed Income Money Market and Derivatives Association of India (FIMMDA). Biocon obtained consent from commercial paper holders and made full buyback of both issues. Company Secretary and Compliance Officer Rajesh U. Shanoy signed the regulatory communication, ensuring proper corporate governance standards.

Biocon Limited has notified stock exchanges about receiving a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for one of its API manufacturing facilities. The pharmaceutical company disclosed this regulatory development through official communications to both major Indian stock exchanges on January 28, 2026.

Facility Details and Inspection Timeline

The VAI status pertains to Biocon's API facility situated at a specific location in Andhra Pradesh. The US FDA conducted its inspection over a five-day period, providing a comprehensive assessment of the manufacturing operations.

Regulatory Compliance and Disclosure

Biocon has fulfilled its disclosure obligations by informing both BSE Limited and National Stock Exchange of India Limited about this regulatory development. The company's notification was signed by Rajesh Umakant Shanoy, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed.

The pharmaceutical company has also made this information available on its official website at www.biocon.com , providing transparency to all stakeholders. This disclosure falls under Regulation 30 requirements, which mandate listed companies to inform exchanges about material events that could impact investor decisions.

Communication to Stock Exchanges

The formal notification was addressed to both major Indian stock exchanges with specific reference numbers for tracking purposes.

The company has requested both exchanges to acknowledge receipt of this notification and maintain it on record as part of standard compliance procedures.